Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Bloomfield

Showing results (511-520 of 583) with videos related to

Pageof 59
Sort By:
Leukemia|March 3, 2012
The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemiaS P Whitman, M A Caligiuri, K Maharry, et al.
Blood|May 6, 2010
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyHeiko Becker, Guido Marcucci, Kati Maharry, et al.
Blood|May 9, 2012
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemiaWilliam Blum, Sebastian Schwind, Somayeh S Tarighat, et al.
Blood|September 16, 2010
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySebastian Schwind, Guido Marcucci, Kati Maharry, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 15, 2011
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromesPeter L Greenberg, Eyal Attar, John M Bennett, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 13, 2006
Myelodysplastic syndromes clinical practice guidelines in oncologyPeter L Greenberg, Maria R Baer, John M Bennett, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 14, 2003
A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomesTimothy J Ley, Patrick J Minx, Matthew J Walter, et al.
Blood|October 24, 2002
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)John C Byrd, Krzysztof Mrózek, Richard K Dodge, et al.
Blood Advances|January 17, 2020
Clinical and functional significance of circular RNAs in cytogenetically normal AMLDimitrios Papaioannou, Stefano Volinia, Deedra Nicolet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117Mikkael A Sekeres, Megan Othus, Alan F List, et al.
Pageof 59

Showing results (511-520 of 583) with videos related to

Sort By:
Pageof 59
Leukemia|March 3, 2012
The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemiaS P Whitman, M A Caligiuri, K Maharry, et al.
Blood|May 6, 2010
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyHeiko Becker, Guido Marcucci, Kati Maharry, et al.
Blood|May 9, 2012
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemiaWilliam Blum, Sebastian Schwind, Somayeh S Tarighat, et al.
Blood|September 16, 2010
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySebastian Schwind, Guido Marcucci, Kati Maharry, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 15, 2011
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromesPeter L Greenberg, Eyal Attar, John M Bennett, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 13, 2006
Myelodysplastic syndromes clinical practice guidelines in oncologyPeter L Greenberg, Maria R Baer, John M Bennett, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 14, 2003
A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomesTimothy J Ley, Patrick J Minx, Matthew J Walter, et al.
Blood|October 24, 2002
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)John C Byrd, Krzysztof Mrózek, Richard K Dodge, et al.
Blood Advances|January 17, 2020
Clinical and functional significance of circular RNAs in cytogenetically normal AMLDimitrios Papaioannou, Stefano Volinia, Deedra Nicolet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117Mikkael A Sekeres, Megan Othus, Alan F List, et al.
Pageof 59